[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100642439":3},{"organization":4,"armGroups":7,"interventions":13,"overallOfficials":20,"centralContacts":25,"locations":34,"responsibleParty":69,"collaborators":19,"id":71,"slug":72,"hasResults":73,"nctId":74,"briefTitle":75,"officialTitle":75,"acronym":76,"eligibilityCriteria":77,"healthyVolunteers":73,"sex":78,"minAge":79,"maxAge":80,"enrollmentInfo":81,"targetDuration":19,"studyType":84,"phases":85,"briefSummary":87,"conditions":88,"keywords":91,"overallStatus":37,"whyStopped":19,"lastUpdateSubmitDate":96,"lastUpdatePostDateStruct":97,"startDateStruct":100,"completionDateStruct":102,"leadSponsor":104,"locationsCount":105},{"fullName":5,"class":6},"Karolinska Institutet","OTHER",[8],{"label":9,"type":6,"description":10,"interventionNames":11},"Treatment","All patients will receive the same treatment and serve as their own controls.",[12],"Drug: ALK Alutard SQ Dog",[14],{"type":15,"name":16,"description":17,"armGroupLabels":18,"otherNames":19},"DRUG","ALK Alutard SQ Dog","The study is based on Swedish guidelines with an up-titration period of 13 weeks from 100 SQ to 100.000 SQ. The maximum dose of 100.000 SQ is the given every 6-8 weeks for 3 years.",[9],null,[21],{"name":22,"affiliation":23,"role":24},"Lars Olaf Cardell","Karolinska Institutet, Division of ENT","PRINCIPAL_INVESTIGATOR",[26,31],{"name":27,"role":28,"phone":29,"phoneExt":19,"email":30},"Carl Skröder, MD","CONTACT","+46 41055181","carl.skroder@ki.com",{"name":32,"role":28,"phone":19,"phoneExt":19,"email":33},"Lars Olaf Cardell, Professor","lars-olaf.cardell@ki.se",[35,55],{"facility":36,"status":37,"city":38,"state":39,"zip":40,"country":41,"countryCode":42,"cosmosGeoPoint":43,"geoPoint":48,"contacts":49},"Lund University Hospital","RECRUITING","Lund","Skåne County","23152","Sweden","SE",{"type":44,"coordinates":45},"Point",[46,47],13.19321,55.70584,{"lat":47,"lon":46},[50,54],{"name":51,"role":28,"phone":52,"phoneExt":19,"email":53},"Franziska Nordström, MD","+46704447341","franziska.nordstrom@skane.se",{"name":32,"role":28,"phone":19,"phoneExt":19,"email":33},{"facility":56,"status":37,"city":57,"state":39,"zip":40,"country":41,"countryCode":42,"cosmosGeoPoint":58,"geoPoint":62,"contacts":63},"Trelleborg Hospital","Trelleborg",{"type":44,"coordinates":59},[60,61],13.15691,55.37514,{"lat":61,"lon":60},[64,66,67],{"name":27,"role":28,"phone":29,"phoneExt":19,"email":65},"carl.skroder@ki.se",{"name":32,"role":28,"phone":19,"phoneExt":19,"email":33},{"name":27,"role":68,"phone":19,"phoneExt":19,"email":19},"SUB_INVESTIGATOR",{"type":24,"investigatorFullName":22,"investigatorTitle":70,"investigatorAffiliation":5,"oldNameTitle":19,"oldOrganization":19},"Professor","100642439","phase-4-evaluation-of-allergen-specific-vaccination-of-dog-allergic-patients-in-swedish-practice-100642439",false,"NCT07651891","Evaluation of ALLERgen Specific Vaccination of DOG Allergic Patients in Swedish Practice","ALLERDOG","Inclusion Criteria\n\nThe subject has provided written informed consent to participate in the study.\n\n* Age 18-50 years.\n* Moderate-to-severe allergic symptoms upon exposure to dogs.\n* Dog allergy confirmed by positive specific IgE.\n* Considered suitable by the investigator for treatment with Alutard SQ Dog in accordance with the approved Summary of Product Characteristics (SmPC).\n* Female subjects of childbearing potential must use adequate contraception.\n* A negative pregnancy test must be obtained prior to enrolment.\n\nExclusion Criteria\n\n* Pregnancy or breastfeeding.\n* Autoimmune or connective tissue disease.\n* Cardiovascular disease.\n* Hepatic disease.\n* Renal disease.\n* Malignancy.\n* Upper airway disease (e.g., non-allergic sinusitis or nasal polyposis).\n* Chronic obstructive or restrictive lung disease.\n* Treatment with medications that may interfere with the immune response.\n* Previous immunotherapy or chemotherapy.\n* Significant chronic disease.\n* Major metabolic disease.\n* Alcohol or substance abuse.\n* Mental or cognitive incapacity that may impair compliance with study procedures.\n* Known or suspected hypersensitivity to the study product.\n* Suspected or confirmed bacterial infection.\n* Clinically relevant allergy to house dust mite.\n* Current dog ownership.\n* Any condition that, in the investigator's opinion, may make participation, follow-up, or study assessments inappropriate.\n* Any subject considered unsuitable for enrolment according to the principles of the Declaration of Helsinki.","ALL","18 Years","50 Years",{"count":82,"type":83},40,"ESTIMATED","INTERVENTIONAL",[86],"PHASE4","STUDY DESIGN A single-center prospective before-and-after study evaluating the effect of Alutard SQ Dog in 40 men and women with moderate-to-severe dog allergy. Participants will serve as their own controls.\n\nSTUDY OUTLINE\n\nThe study will begin in the fall of 2026 and will be conducted over a one-year period. At baseline, participants will be asked to record their allergic symptoms, and assessments of lung function and nasal airflow will be performed. Blood samples will also be collected.\n\nFollowing the baseline assessments, participants will undergo allergen provocation by entering a facility containing dogs. After a 30-minute exposure to dogs, participants will again be asked to record their allergic symptoms and will undergo the same assessments performed at baseline.\n\nAllergen immunotherapy (AIT) with Alutard SQ Dog will then be initiated according to the standard treatment regimen and continued for one year. At the end of the treatment period, the same provocation procedure and assessments will be repeated. Participants will enter a facility containing dogs, followed by symptom recording and evaluation of lung function, nasal airflow, and relevant laboratory parameters.",[89,90],"Allergic Rhinitis","Asthma (Diagnosis)",[92,93,94,95],"AIT","SCIT","Allergic rhinitis","Asthma","2026-06-24",{"date":98,"type":99},"2026-06-29","ACTUAL",{"date":101,"type":83},"2026-08-01",{"date":103,"type":83},"2027-12-01",{"name":5,"class":6},2]